Toward tailored medicine (and beyond): The phaeochromocytoma and paraganglioma model

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 8, 2012, Pages 1262-1265

  Cuccurull, Vincenzo ^a   Mansi, Luigi ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 5 HYDROXYTRYPTOPHAN; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; AMINO ACID DECARBOXYLASE; CD98 ANTIGEN; CHROMOGRANIN A; DOTA 1 NAL3 OCTREOTIDE; DOTA PHENYLALANINE TYROSINE 3 OCTREOTATE; DOTA TYROSINE 3 OCTREOTATE; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; SOMATOSTATIN DERIVATIVE; SUCCIMER TC 99M; SUCCINATE DEHYDROGENASE; TRACER; UNCLASSIFIED DRUG;

ADRENAL MEDULLA; BENIGN CHILDHOOD EPILEPSY; BONE METASTASIS; CANCER PROGNOSIS; CANCER SURGERY; CHROMAFFIN CELL; COST EFFECTIVENESS ANALYSIS; DOSIMETRY; HUMAN; LIVER METASTASIS; MALIGNANT NEOPLASTIC DISEASE; NEURAL CREST; NEUROSECRETORY CELL; NOTE; PARAGANGLIOMA; PARAGANGLION; PERSONALIZED MEDICINE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; HUMANS; ORGANOMETALLIC COMPOUNDS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84865514796     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2156-2     Document Type: Note

References (16)

1. Maurice JB, Troke R,Win Z, Ramachandran R, Al-Nahhas A, Naji M, et al. A comparison of the performance of (68)Ga-DOTATATE PET/CT and (123)I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012. doi:10.1007/s00259-012-2119-7.
2. Fliedner SM, Lehnert H, Pacak K. Metastatic paraganglioma. Semin Oncol. 2010;37(6):627-37.
3. Andersen KF, Altaf R, Krarup-Hansen A, Kromann-Andersen B, Horn T, Christensen NJ, et al. Malignant pheochromocytomas and paragangliomas -the importance of a multidisciplinary approach. Cancer Treat Rev. 2011;37(2):111-9.
4. Havekes B, Lai EW, Corssmit EP, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging. 2008;52(4):419-29.
5. Ambrosini V, Tomassetti P, Franchi R, Fanti S. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2010;54(1):16-23.
6. Vaidyanathan G. Meta-iodobenzylguanidine and analogues: chemistry and biology. Q J Nucl Med Mol Imaging. 2008;52(4):351-68.
7. Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, et al. False-negative I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2012;19(1):83-93.
8. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95(6):2800-10.
9. Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nucl Med. 2011;36(1):1-7.
10. Minn H, Kauhanen S, Seppänen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50(12):1915-8.
11. King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D- glucose PET, 123Imetaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96(9):2779-85.
12. Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun. 2011;32(7):575-82.
13. Mansi L, Virgolini I. Diagnosis and therapy are walking together on radiopeptides' avenue. Eur J Nucl Med Mol Imaging. 2011;38 (4):605-12.
14. Naji M, L-Nahhas A. 68Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S61-7.
15. Nakazawa A, Higuchi T, Oriuchi N, Arisaka Y, Endo K. Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma. Eur J Nucl Med Mol Imaging. 2011;38(10):1869-75.
16. Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, Marvelle AF, et al. Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer. 2011;18(1):143-57.